Table 2.
Local DDS in periodontitis.
| Devices | Polymers * | Drug | Suistained Release Time |
|---|---|---|---|
| fibers | PLGA 1,GT 2 [36] | tetracycline hydrochloride |
75 days |
| biodegradable polydioxanone [116] |
metronidazole or ciprofloxacin |
over 7 days | |
| rings/ strips |
trimethylene TMC 3/CL 4,GL 5/CL [117] |
doxycycline hyclate | 28 days |
| films | PEGylated rosin derivatives(PRDs) [118] |
sparfloxacin | over 21 days |
| Gelatin [119] | curcumin | up to 7 days | |
| Chitosan [120] | Metronidazole, levofloxacin |
up to 7 days | |
| PEO 6, PDLLA 7 [121] | Lipoxin A4 | 48h | |
| chitosan, PVA [120] | doxycyclin | over 1 week | |
| in situ gel/ impants |
PLGA, NMP 8 [122] | Minocycline | over 48 h |
| Pluronic F127, carbopol P934 [123] |
curcumin | over 1 week | |
| Pluronic, Carbopol [124] |
meloxicam or minocycline HCl |
3 days for MH, 7 days for Mx |
|
| Cholesterol, NMP [125] |
doxycycline hyclate | 10 days | |
| NMP, Ethylcellulose, bleached shellac, Eudragit RS [126] |
NMP | / | |
| mPEG-PDLLA [55] | tinidazole | 192 h | |
| Carbopol 934P, Polaxamer 407 [127] |
ketoprofen | over 24 h | |
| PLGA, calcium phosphate Cements [41] |
BMP-2, FGF-2 | / | |
| PLGA, NMP [128] | metronidazole | over 10 days | |
| micro-/ nano-particles |
BS 9, NMP, DMSO 10, GMS 11 [129] |
doxycycline hyclate | 47 days |
| PLGA [36] | doxycycline hyclate | at least 15days | |
| Chitosan [130] | clindamycin phosphate | more than 1 week | |
| PEG 12, PLA 13, RGD peptide [131] |
minocycline | 14 days | |
| Nanoparticles [132] | tetracycline | over 5 days |
* The polymer carriers of DDS were showed in abbreviation: 1 PLGA: poly lactic glycolic acid; 2 GT: gum tragacanth; 3 TMC: trimethylene carbonate; 4 CL: caprolactone; 5 GL: glycolide; 6 PEO: poly(ethylene oxide; 7 PDLLA: poly(d,l-lactide); 8 NMP: N-methylpyrrolidone; 9 BS: Bleached shellac; 10 DMSO: dimethyl sulfoxide; 11 GMS: 2-pyrrolidone, glyceryl monostearate; 12 PEG: poly(ethylene glycol); 13 PLA: poly(lactic acid).